Cytosorbents (NASDAQ:CTSO) CEO Acquires $100,454.40 in Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan acquired 251,136 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average price of $0.40 per share, with a total value of $100,454.40. Following the completion of the acquisition, the chief executive officer owned 1,734,099 shares of the company’s stock, valued at $693,639.60. This represents a 16.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Cytosorbents Stock Up 8.1%

Shares of NASDAQ:CTSO traded up $0.03 during midday trading on Monday, hitting $0.43. 228,497 shares of the stock were exchanged, compared to its average volume of 102,332. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. Cytosorbents Corporation has a 52-week low of $0.37 and a 52-week high of $1.39. The business’s fifty day simple moving average is $0.55 and its two-hundred day simple moving average is $0.64. The company has a market capitalization of $27.13 million, a PE ratio of -2.27 and a beta of 1.35.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Cytosorbents had a negative return on equity of 235.57% and a negative net margin of 31.85%.The firm had revenue of $8.86 million for the quarter, compared to analysts’ expectations of $9.40 million. As a group, research analysts predict that Cytosorbents Corporation will post -0.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on CTSO. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Thursday, March 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a report on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.38.

Hedge Funds Weigh In On Cytosorbents

Hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its position in Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares during the last quarter. Citadel Advisors LLC increased its position in Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after buying an additional 36,790 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Cytosorbents during the third quarter worth $105,000. CIBC Bancorp USA Inc. acquired a new position in Cytosorbents during the third quarter worth $161,000. Finally, CM Management LLC increased its position in Cytosorbents by 3.1% during the third quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after buying an additional 38,128 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.